Titre :
  • An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
Auteur : Awada, Ahmad ; Thödtmann, R ; Piccart-Gebhart, Martine ; Wanders, Jantien ; Schrijvers, A H G J ; Von Broen, I-M ; Hanauske, Axel-R ; EORTC-ECSG phase I study
Informations sur la publication : European journal of cancer, 39, 6, (page 742-747)
Statut de publication : Publié, 2003-04
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Aged
Amides -- administration & dosage
Amides -- adverse effects
Amides -- pharmacokinetics
Antineoplastic Agents -- administration & dosage
Antineoplastic Agents -- adverse effects
Antineoplastic Agents -- pharmacokinetics
Cohort Studies
Drug Administration Schedule
Female
Half-Life
Humans
Infusions, Intravenous
Isoquinolines -- administration & dosage
Isoquinolines -- adverse effects
Isoquinolines -- pharmacokinetics
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms -- drug therapy
Note : Clinical Trial
Clinical Trial, Phase I
Journal Article
Langue :
  • Anglais
Identificateurs : urn:issn:0959-8049 
info:pii/S0959804902007761
info:pmid/12651198